SciFounders

Olio Labs is a biotechnology company focused on developing combination therapeutics that leverage artificial intelligence to enhance treatment efficacy and reduce side effects. By employing automated discovery methods, the company analyzes protein interactions in the body, allowing for a more comprehensive approach to therapeutic design. Unlike traditional methods that typically target a limited number of proteins, Olio Labs' innovative strategy aims to create effective treatment solutions that consider a wider range of interacting proteins, ultimately improving patient outcomes.

Current Surgical is a surgical device company founded in 2020 and based in Washington, DC. The company specializes in the development of innovative tools aimed at the treatment of solid tumors. Its flagship product is a smart surgical needle designed for minimally invasive tumor detection and ablation. This advanced needle utilizes real-time X-ray guidance combined with ultrasound energy to heat and destroy tumors while preserving surrounding vital organs and tissues. This technology enables surgeons to effectively target tumors located near critical anatomical structures, enhancing surgical precision and patient safety.

Luminate Medical is a company focused on developing innovative medical devices aimed at preventing hair loss during chemotherapy. Recognizing the significant impact that hair loss can have on a patient's self-esteem and sense of identity, Luminate Medical is committed to leveraging advanced medical technology to address this issue. The company offers a unique, portable, and comfortable wearable system designed to help patients maintain their confidence and dignity throughout their cancer treatment, ultimately enabling them to manage and mitigate the side effects associated with chemotherapy.

ImmTune Therapies specializes in developing a cell and gene therapy platform that simplifies complex biomanufacturing processes. The company focuses on CAR-T-based cell and immune therapies for cancer treatment, designing vectors that facilitate the delivery of chimeric antigen receptors (CARs) to T-cells within the body. This innovative approach aims to enhance the safety and efficiency of delivering therapies directly to tumor cells, enabling clinicians to administer treatments more effectively. By streamlining the production and application of cell therapies, ImmTune Therapies seeks to reduce the costs associated with treatment, making these advanced therapies more accessible to patients.

Engage Bio is developing mRNA treatments that change cancer cells into production facilities for immunotherapies. With the help of these treatments, the immune system is activated and directed toward the tumour.

Inherent Targeting develops fluorescent contrast agents that target nerves to improve surgical outcomes. The company was founded in 2019 and is headquartered in Portland, Oregon.

Symphony Biosciences is a biotechnology company dedicated to developing innovative cancer treatments that target solid tumors, with a primary focus on triple-negative breast cancer. Recognizing the limitations of existing therapies, which often involve toxic chemotherapies with poor survival rates, Symphony Biosciences aims to orchestrate the immune response to improve outcomes for patients. The company's research emphasizes the use of biomaterials to enhance cancer treatment options, providing healthcare professionals with effective tools to combat challenging cancer types. Through its focused efforts, Symphony Biosciences strives to advance the field of oncology and improve the quality of care for patients facing solid tumors.

ImmTune Therapies specializes in developing a cell and gene therapy platform that simplifies complex biomanufacturing processes. The company focuses on CAR-T-based cell and immune therapies for cancer treatment, designing vectors that facilitate the delivery of chimeric antigen receptors (CARs) to T-cells within the body. This innovative approach aims to enhance the safety and efficiency of delivering therapies directly to tumor cells, enabling clinicians to administer treatments more effectively. By streamlining the production and application of cell therapies, ImmTune Therapies seeks to reduce the costs associated with treatment, making these advanced therapies more accessible to patients.

Current Surgical is a surgical device company founded in 2020 and based in Washington, DC. The company specializes in the development of innovative tools aimed at the treatment of solid tumors. Its flagship product is a smart surgical needle designed for minimally invasive tumor detection and ablation. This advanced needle utilizes real-time X-ray guidance combined with ultrasound energy to heat and destroy tumors while preserving surrounding vital organs and tissues. This technology enables surgeons to effectively target tumors located near critical anatomical structures, enhancing surgical precision and patient safety.